What is Acetyl Hexapeptide-30?
Acetyl Hexapeptide-30 (trade name INYLINE) is a synthetic acetylated hexapeptide developed by Lipotec (now Lubrizol) as a cosmetic active for expression-line reduction. It is positioned as a newer-generation alternative to Argireline (Acetyl Hexapeptide-8/Acetyl Hexapeptide-3), offering a different mechanism at the neuromuscular junction.
It is widely used in commercial anti-aging skincare formulations marketed for crow's feet, forehead lines, and glabellar (between-the-brows) wrinkles. Inyline is a cosmetic ingredient, not a drug.
Structure
Acetyl Hexapeptide-30 is a six-residue synthetic peptide with N-terminal acetylation (the precise sequence is proprietary to Lipotec/Lubrizol but is in the public ingredient databases as "Acetyl Hexapeptide-30").
Mechanism of Action
Whereas Argireline (Acetyl Hexapeptide-8) acts presynaptically by mimicking the SNAP-25 N-terminus and disrupting the SNARE complex assembly required for acetylcholine release, Acetyl Hexapeptide-30 acts at a different point in neuromuscular transmission:
- Antagonist of MuSK-Agrin binding at the postsynaptic neuromuscular junction
- MuSK (muscle-specific kinase) is activated by Agrin to cluster acetylcholine receptors at the postsynaptic muscle membrane
- Inyline blocks this Agrin-MuSK interaction
- Reduced AChR clustering → reduced functional muscle response to motor neuron firing
- Expression-line muscles relax with chronic topical application
This postsynaptic mechanism complements Argireline's presynaptic mechanism — the two are sometimes combined in anti-aging products for additive effects.
Cosmetic Use
Inyline is incorporated into anti-aging skincare at typical concentrations of 5-10% Inyline solution (where the solution itself contains a defined concentration of the peptide). Marketed for:
- Crow's feet (lateral canthal lines)
- Forehead lines and glabellar wrinkles
- Expression-line reduction in dynamic facial areas
Effects develop gradually over weeks of consistent application. Comparative claims vs Argireline include improved tolerability and complementary mechanism for combination use.
Place in Expression-Line Cosmetic Peptide Family
| Peptide | Trade Name | Synaptic Target | Mechanism |
|---|---|---|---|
| Argireline | Argireline | Presynaptic | SNARE/SNAP-25 disruption (botulinum-mimetic peptide) |
| Acetyl Hexapeptide-30 | Inyline | Postsynaptic | MuSK-Agrin blockade |
| Pentapeptide-18 | Leuphasyl | Presynaptic | Enkephalin-mimetic, opens K+ channels |
| SNAP-8 (Acetyl Octapeptide-3) | SNAP-8 | Presynaptic | Extended SNARE/SNAP-25 disruption |
This family of "neuropeptide-mimetic" cosmetic peptides all target neuromuscular transmission to reduce expression lines, with each targeting a different molecular step.
Safety Profile
Excellent safety profile in cosmetic use:
- No documented systemic absorption to clinically meaningful levels
- Rare contact irritation, generally mild
- Suitable for daily long-term use
- Compatible with most active formulations
Note on Cosmetic Status
Inyline, like Argireline and other "Botox-mimetic" cosmetic peptides, is regulated as a cosmetic ingredient, not a drug. It cannot make medical claims. The pharmacological effects on neuromuscular transmission are real but modest and gradual compared to the directly muscle-paralyzing effects of injected botulinum toxin (Botox, Daxxify). Patient expectations should be calibrated accordingly.